Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia

This single-arm, open-label, phase 1b study evaluated the maximum tolerated dose (MTD) of venetoclax when given with obinutuzumab and its safety and tolerability in patients with relapsed/refractory (R/R) or previously untreated (first line [1L]) chronic lymphocytic leukemia (CLL). Venetoclax dose i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Flinn, Ian W., Gribben, John G., Dyer, Martin J. S., Wierda, William, Maris, Michael B., Furman, Richard R., Hillmen, Peter, Rogers, Kerry A., Iyer, Swaminathan Padmanabhan, Quillet-Mary, Anne, Ysebaert, Loic, Walter, Harriet S., Verdugo, Maria, Klein, Christian, Huang, Huang, Jiang, Yanwen, Lozanski, Gerard, Pignataro, Daniela Soriano, Humphrey, Kathryn, Mobasher, Mehrdad, Kipps, Thomas J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6706803/
https://ncbi.nlm.nih.gov/pubmed/30862645
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2019-01-896290
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados